144 related articles for article (PubMed ID: 12644579)
1. Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens.
Terouanne B; Nirdé P; Rabenoelina F; Bourguet W; Sultan C; Auzou G
Mol Pharmacol; 2003 Apr; 63(4):791-8. PubMed ID: 12644579
[TBL] [Abstract][Full Text] [Related]
2. Glutamic acid 709 substitutions highlight the importance of the interaction between androgen receptor helices H3 and H12 for androgen and antiandrogen actions.
Georget V; Bourguet W; Lumbroso S; Makni S; Sultan C; Nicolas JC
Mol Endocrinol; 2006 Apr; 20(4):724-34. PubMed ID: 16373394
[TBL] [Abstract][Full Text] [Related]
3. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiandrogens on transformation and transcription activation of wild-type and mutated (LNCaP) androgen receptors.
Berrevoets CA; Veldscholte J; Mulder E
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):731-6. PubMed ID: 8274406
[TBL] [Abstract][Full Text] [Related]
6. Specific recognition of androgens by their nuclear receptor. A structure-function study.
Poujol N; Wurtz JM; Tahiri B; Lumbroso S; Nicolas JC; Moras D; Sultan C
J Biol Chem; 2000 Aug; 275(31):24022-31. PubMed ID: 10787411
[TBL] [Abstract][Full Text] [Related]
7. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
8. Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation.
Warriar N; Pagé N; Koutsilieris M; Govindan MV
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):699-711. PubMed ID: 8274404
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.
Bohl CE; Wu Z; Miller DD; Bell CE; Dalton JT
J Biol Chem; 2007 May; 282(18):13648-55. PubMed ID: 17311914
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
11. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei.
Karvonen U; Jänne OA; Palvimo JJ
FEBS Lett; 2002 Jul; 523(1-3):43-7. PubMed ID: 12123801
[TBL] [Abstract][Full Text] [Related]
12. Antimineralocorticoid 11beta-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study.
Nirdé P; Térouanne B; Gallais N; Sultan C; Auzou G
Mol Pharmacol; 2001 May; 59(5):1307-13. PubMed ID: 11306716
[TBL] [Abstract][Full Text] [Related]
13. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
Ghali SA; Gottlieb B; Lumbroso R; Beitel LK; Elhaji Y; Wu J; Pinsky L; Trifiro MA
J Clin Endocrinol Metab; 2003 May; 88(5):2185-93. PubMed ID: 12727974
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone.
Kemppainen JA; Langley E; Wong CI; Bobseine K; Kelce WR; Wilson EM
Mol Endocrinol; 1999 Mar; 13(3):440-54. PubMed ID: 10077001
[TBL] [Abstract][Full Text] [Related]
15. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line.
Paris F; Rabeolina F; Balaguer P; Bacquet A; Sultan C
Gynecol Endocrinol; 2007 Apr; 23(4):193-7. PubMed ID: 17505938
[TBL] [Abstract][Full Text] [Related]
16. A naturally occurring mutation in the human androgen receptor of a subject with complete androgen insensitivity confers binding and transactivation by estradiol.
Bonagura TW; Deng M; Brown TR
Mol Cell Endocrinol; 2007 Jan; 263(1-2):79-89. PubMed ID: 17011702
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
Song LN; Coghlan M; Gelmann EP
Mol Endocrinol; 2004 Jan; 18(1):70-85. PubMed ID: 14593076
[TBL] [Abstract][Full Text] [Related]
18. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogens: selective androgen receptor modulators.
Berrevoets CA; Umar A; Brinkmann AO
Mol Cell Endocrinol; 2002 Dec; 198(1-2):97-103. PubMed ID: 12573819
[TBL] [Abstract][Full Text] [Related]
20. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations.
Matias PM; Donner P; Coelho R; Thomaz M; Peixoto C; Macedo S; Otto N; Joschko S; Scholz P; Wegg A; Bäsler S; Schäfer M; Egner U; Carrondo MA
J Biol Chem; 2000 Aug; 275(34):26164-71. PubMed ID: 10840043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
